FER Inhibitors
1 drugsAbout FER
FER, or tyrosine-protein kinase FER, is a non-receptor tyrosine kinase involved in cell signaling and regulation. As an enzyme, it regulates cellular functions by adding phosphate groups to proteins, a process called phosphorylation. Aberrant kinase activity is frequently implicated in disease, driving uncontrolled cell growth.
FER is a compelling target in oncology, though there is currently no genetic evidence data linking FER directly to specific diseases. The existence of an approved drug targeting FER suggests its involvement in cancer pathways, warranting further research to elucidate its role.
FER is currently targeted by one FDA-approved drug, LORBRENA (Pfizer), a small molecule used in oncology. LORBRENA was first approved in 2018, and no other drugs have been approved since.
Top FER Drugs
Pfizer is the only company with an approved drug targeting FER.
The market is not competitive, presenting an opportunity for other companies to enter the space.
FER Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets FER, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
FER Clinical Trials 36 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FER. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 6 | 3 | 3 | 67% |
| Phase 2 | 16 | 3 | 3 | 10 | 50% |
| Phase 3 | 3 | 0 | 0 | 3 | - |
| Phase 4 | 5 | 2 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FER Drug Approval Timeline (2018 - 2018)
The first and only drug targeting FER, LORBRENA, was approved in 2018.
The lack of recent approvals suggests either a challenging target or an untapped opportunity for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 23 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FER. A trial counts if an approved drug acting on FER is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.